Bitterroot Launches with $145M Series A to Advance Cardio-Immuno Therapies

California-based start-up Bitterroot Bio has launched with a focus on developing immunotherapies for cardiovascular diseases, following a successful $145m series A funding round. The company was founded by Irving Weissman and Nicholas Leeper from the Stanford University School of Medicine in 2021 and is focused on cardio-immunology. Its lead programme, BRB-002 targets CD47/SIRPα pathways underly..